<!DOCTYPE html>
<html lang="en" dir="ltr" 
  xmlns="http://www.w3.org/1999/xhtml"
  xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#" >
    <!--[if IE]><![endif]-->
<link rel="dns-prefetch" href="//d33xdlntwy0kbs.cloudfront.net" />
<link rel="dns-prefetch" href="//www.google.com" />
<link rel="dns-prefetch" href="//scholar.google.com" />
<link rel="dns-prefetch" href="//www.google-analytics.com" />
<link rel="dns-prefetch" href="//stats.g.doubleclick.net" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link rel="shortcut icon" href="https://www.medrxiv.org/sites/default/files/images/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" type="application/pdf" title="Full Text (PDF)" href="/content/10.1101/2021.10.22.21265327v1.full.pdf" />
<link rel="alternate" type="text/plain" title="Full Text (Plain)" href="/content/10.1101/2021.10.22.21265327v1.full.txt" />
<link rel="alternate" type="application/vnd.ms-powerpoint" title="Powerpoint" href="/content/10.1101/2021.10.22.21265327v1.ppt" />
<meta name="type" content="article" />
<meta name="category" content="article" />
<meta name="HW.identifier" content="/medrxiv/early/2021/10/25/2021.10.22.21265327.atom" />
<meta name="HW.pisa" content="medrxiv;2021.10.22.21265327v1" />
<meta name="DC.Format" content="text/html" />
<meta name="DC.Language" content="en" />
<meta name="DC.Title" content="Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial" />
<meta name="DC.Identifier" content="10.1101/2021.10.22.21265327" />
<meta name="DC.Date" content="2021-10-25" />
<meta name="DC.Publisher" content="Cold Spring Harbor Laboratory Press" />
<meta name="DC.Rights" content="© 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/" />
<meta name="DC.AccessRights" content="restricted" />
<meta name="DC.Description" content="Introduction Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with preclinical data suggesting the combination of dexamethasone with the MEK1/2 inhibitor, selumetinib (ARRY-142886), results in a potent synergistic anti-cancer effect.

Methods and analysis The SeluDex trial is an international, parallel-group, dose-finding with expansion, phase I/II trial to assess the selumetinib/dexamethasone combination in adult and paediatric patients with relapsed/refractory, RAS pathway mutant ALL. The Cancer Research UK Clinical Trials Unit at University of Birmingham is the UK Coordinating Centre, with national hubs in Copenhagen, Denmark; Monza, Italy; Münster, Germany; Paris, France; and Utrecht, Netherlands. Paediatric centres are all part of the Innovative Therapies for Children with Cancer consortium. Patients with morphologically proven relapsed/refractory or progressive B-cell precursor or T-ALL, with demonstrated RAS pathway activating mutations are eligible. Adult patients are ≥18 years old, ECOG ≤2 and paediatric &lt;18 years old, Lansky play scale ≥60% or Karnofsky score ≥60%. The primary objective in phase I is to determine the recommended phase II dose of selumetinib as defined by occurrence/non-occurrence of dose limiting toxicities using the continual reassessment method, and phase II will evaluate preliminary anti-leukaemic activity of the selumetinib/dexamethasone combination, as defined by morphological response 28 days post treatment using a Bayesian approach. Target recruitment is between 26 and 42 patients (minimum of 13 and maximum of 21 in each group), depending on how many phase I patients are included also in phase II.

Ethics and dissemination Medical ethical committees of all the participating countries will approve the study protocol. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.

Trial registration number The trial was registered on EudraCT 2016-003904-29 on 21st September 2016, [ISRCTN 92323261][1], [ClinicalTrials.Gov][2] [NCT03705507][3], and ITCC-063 study.

Strengths and limitations of this study 

### Competing Interest Statement

JI has received research funding from F. Hoffmann-La Roche Ltd. All other authors declare no other relevant conflicts of interest.

### Clinical Trial

NCT03705507

### Funding Statement

This work is supported by Cancer Research UK (C27943/A22304), CRUK trial number CRUKD/16/015 and (C27943/A23260), CRUK trial number CRUKD/16/016, and AstraZeneca through the CRUK’s Combinations Alliance and Experimental Cancer Medicine Centre (ECMC). AstraZeneca provides Selumetinib to participating sites free-of-charge, and was consulted over the trial design but are not involved in the trial management group or safety committee. National Coordinating Centres were supported by a grant from ITCC ‘Imagine for Margo’ fund and AstraZeneca. Staff at the CRCTU are also supported by a core funding grant from Cancer Research UK (C22436/A25354).

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yorkshire &amp; The Humber - Leeds West Research Ethics Committee gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Participant data and the associated supporting documentation will be available within 6 months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director’s Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham’s IT guidance on encryption of data sets.

 [1]: /external-ref?link_type=ISRCTN&amp;access_num=ISRCTN92323261
 [2]: http://ClinicalTrials.Gov
 [3]: /lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT03705507&amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F25%2F2021.10.22.21265327.atom" />
<meta name="DC.Contributor" content="Tobias Menne" />
<meta name="DC.Contributor" content="Daniel Slade" />
<meta name="DC.Contributor" content="Joshua Savage" />
<meta name="DC.Contributor" content="Sarah Johnson" />
<meta name="DC.Contributor" content="Julie Irving" />
<meta name="DC.Contributor" content="Pamela R. Kearns" />
<meta name="DC.Contributor" content="Ruth Plummer" />
<meta name="DC.Contributor" content="Geoff Shenton" />
<meta name="DC.Contributor" content="Gareth J. Veal" />
<meta name="DC.Contributor" content="Britta Vormoor" />
<meta name="DC.Contributor" content="Josef Vormoor" />
<meta name="DC.Contributor" content="Lucinda Billingham" />
<meta name="article:published_time" content="2021-10-25" />
<meta name="citation_title" content="Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial" />
<meta name="citation_abstract" lang="en" content="&lt;p&gt;Introduction
Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with preclinical data suggesting the combination of dexamethasone with the MEK1/2 inhibitor, selumetinib (ARRY-142886), results in a potent synergistic anti-cancer effect.
Methods and analysis
The SeluDex trial is an international, parallel-group, dose-finding with expansion, phase I/II trial to assess the selumetinib/dexamethasone combination in adult and paediatric patients with relapsed/refractory, RAS pathway mutant ALL. The Cancer Research UK Clinical Trials Unit at University of Birmingham is the UK Coordinating Centre, with national hubs in Copenhagen, Denmark; Monza, Italy; Munster, Germany; Paris, France; and Utrecht, Netherlands. Paediatric centres are all part of the Innovative Therapies for Children with Cancer consortium. Patients with morphologically proven relapsed/refractory or progressive B-cell precursor or T-ALL, with demonstrated RAS pathway activating mutations are eligible. Adult patients are &amp;gt;18 years old, ECOG &amp;lt;2 and paediatric &amp;lt;18 years old, Lansky play scale ≥60% or Karnofsky score ≥60%. The primary objective in phase I is to determine the recommended phase II dose of selumetinib as defined by occurrence/non-occurrence of dose limiting toxicities using the continual reassessment method, and phase II will evaluate preliminary anti-leukaemic activity of the selumetinib/dexamethasone combination, as defined by morphological response 28 days post treatment using a Bayesian approach. Target recruitment is between 26 and 42 patients (minimum of 13 and maximum of 21 in each group), depending on how many phase I patients are included also in phase II.
Ethics and dissemination
Medical ethical committees of all the participating countries will approve the study protocol. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications. 
Trial registration number
The trial was registered on EudraCT 2016-003904-29 on 21st September 2016, ISRCTN 92323261, ClinicalTrials.Gov NCT03705507, and ITCC-063 study.&lt;/p&gt;" />
<meta name="citation_journal_title" content="medRxiv" />
<meta name="citation_publisher" content="Cold Spring Harbor Laboratory Press" />
<meta name="citation_publication_date" content="2021/01/01" />
<meta name="citation_mjid" content="medrxiv;2021.10.22.21265327v1" />
<meta name="citation_id" content="2021.10.22.21265327v1" />
<meta name="citation_public_url" content="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" />
<meta name="citation_abstract_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1.abstract" />
<meta name="citation_full_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1.full" />
<meta name="citation_pdf_url" content="https://www.medrxiv.org/content/medrxiv/early/2021/10/25/2021.10.22.21265327.full.pdf" />
<meta name="citation_doi" content="10.1101/2021.10.22.21265327" />
<meta name="citation_num_pages" content="24" />
<meta name="citation_article_type" content="Article" />
<meta name="citation_firstpage" content="2021.10.22.21265327" />
<meta name="citation_author" content="Tobias Menne" />
<meta name="citation_author_institution" content="Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust" />
<meta name="citation_author" content="Daniel Slade" />
<meta name="citation_author_institution" content="Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham" />
<meta name="citation_author" content="Joshua Savage" />
<meta name="citation_author_institution" content="Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham" />
<meta name="citation_author_orcid" content="http://orcid.org/0000-0003-0599-0245" />
<meta name="citation_author" content="Sarah Johnson" />
<meta name="citation_author_institution" content="Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham" />
<meta name="citation_author" content="Julie Irving" />
<meta name="citation_author_institution" content="Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University" />
<meta name="citation_author" content="Pamela R. Kearns" />
<meta name="citation_author_institution" content="Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham" />
<meta name="citation_author" content="Ruth Plummer" />
<meta name="citation_author_institution" content="Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust" />
<meta name="citation_author_institution" content="Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University" />
<meta name="citation_author" content="Geoff Shenton" />
<meta name="citation_author_institution" content="Great North Children’s Hospital, Royal Victoria Infirmary Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust" />
<meta name="citation_author" content="Gareth J. Veal" />
<meta name="citation_author_institution" content="Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University" />
<meta name="citation_author" content="Britta Vormoor" />
<meta name="citation_author_institution" content="Princess Máxima Center for Paediatric Oncology" />
<meta name="citation_author" content="Josef Vormoor" />
<meta name="citation_author_institution" content="Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University" />
<meta name="citation_author_institution" content="Princess Máxima Center for Paediatric Oncology" />
<meta name="citation_author_institution" content="University Medical Center" />
<meta name="citation_author" content="Lucinda Billingham" />
<meta name="citation_author_institution" content="Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust" />
<meta name="citation_author_email" content="L.J.Billingham@bham.ac.uk" />
<meta name="citation_author_orcid" content="http://orcid.org/0000-0001-8581-4262" />
<meta name="citation_reference" content="Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–85." />
<meta name="citation_reference" content="Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol. 2005;23(31):7942–50." />
<meta name="citation_reference" content="Bassan R, Hoelzer D. Modern Therapy of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2011;29(5):532–43." />
<meta name="citation_reference" content="Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017;129(13):1878–81." />
<meta name="citation_reference" content="Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420–30." />
<meta name="citation_reference" content="Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics. 2017;49(8):1211–8." />
<meta name="citation_reference" content="Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, et al. The role of the RAS pathway in iAMP21-ALL. Leukemia. 2016;30(9):1824–31." />
<meta name="citation_reference" content="Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–63." />
<meta name="citation_reference" content="Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(11):3080–7." />
<meta name="citation_reference" content="Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine. 2014;371(11):1005–15." />
<meta name="citation_reference" content="Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242–52." />
<meta name="citation_reference" content="Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208(5):901–8." />
<meta name="citation_reference" content="Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932–9." />
<meta name="citation_reference" content="Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14(12):3716–21." />
<meta name="citation_reference" content="Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer. 2014;50(2):406–10." />
<meta name="citation_reference" content="Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J Clin Oncol. 2018;36(12):1232–9." />
<meta name="citation_reference" content="Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017;3(4):516–22." />
<meta name="citation_reference" content="Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, et al. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018;78(18):5398–407." />
<meta name="citation_reference" content="Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47." />
<meta name="citation_reference" content="Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, et al. Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica. 2019;104(9):1804–11." />
<meta name="citation_reference" content="McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68(4):356–66." />
<meta name="citation_reference" content="Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017;19(8):1135–44." />
<meta name="citation_reference" content="Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375(26):2550–60." />
<meta name="citation_reference" content="O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46(1):33149–48." />
<meta name="citation_reference" content="Program CTE. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. US Department of Health and Human Services, NIH, NCI. 2010." />
<meta name="citation_reference" content="O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo j. 1998;17(2):384–95." />
<meta name="citation_reference" content="Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14(11):1149–61." />
<meta name="citation_reference" content="Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648–54." />
<meta name="citation_reference" content="Nie Y, Lu W, Chen D, Tu H, Guo Z, Zhou X, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomarker Research. 2020;8(1):18." />
<meta name="citation_reference" content="Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, et al. How to design a dose-finding study using the continual reassessment method. BMC Medical Research Methodology. 2019;19(1):18." />
<meta name="twitter:title" content="Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial" />
<meta name="twitter:site" content="@medrxivpreprint" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:description" content="Introduction Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with preclinical data suggesting the combination of dexamethasone with the MEK1/2 inhibitor, selumetinib (ARRY-142886), results in a potent synergistic anti-cancer effect.

Methods and analysis The SeluDex trial is an international, parallel-group, dose-finding with expansion, phase I/II trial to assess the selumetinib/dexamethasone combination in adult and paediatric patients with relapsed/refractory, RAS pathway mutant ALL. The Cancer Research UK Clinical Trials Unit at University of Birmingham is the UK Coordinating Centre, with national hubs in Copenhagen, Denmark; Monza, Italy; Münster, Germany; Paris, France; and Utrecht, Netherlands. Paediatric centres are all part of the Innovative Therapies for Children with Cancer consortium. Patients with morphologically proven relapsed/refractory or progressive B-cell precursor or T-ALL, with demonstrated RAS pathway activating mutations are eligible. Adult patients are ≥18 years old, ECOG ≤2 and paediatric &lt;18 years old, Lansky play scale ≥60% or Karnofsky score ≥60%. The primary objective in phase I is to determine the recommended phase II dose of selumetinib as defined by occurrence/non-occurrence of dose limiting toxicities using the continual reassessment method, and phase II will evaluate preliminary anti-leukaemic activity of the selumetinib/dexamethasone combination, as defined by morphological response 28 days post treatment using a Bayesian approach. Target recruitment is between 26 and 42 patients (minimum of 13 and maximum of 21 in each group), depending on how many phase I patients are included also in phase II.

Ethics and dissemination Medical ethical committees of all the participating countries will approve the study protocol. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.

Trial registration number The trial was registered on EudraCT 2016-003904-29 on 21st September 2016, [ISRCTN 92323261][1], [ClinicalTrials.Gov][2] [NCT03705507][3], and ITCC-063 study.

Strengths and limitations of this study 

### Competing Interest Statement

JI has received research funding from F. Hoffmann-La Roche Ltd. All other authors declare no other relevant conflicts of interest.

### Clinical Trial

NCT03705507

### Funding Statement

This work is supported by Cancer Research UK (C27943/A22304), CRUK trial number CRUKD/16/015 and (C27943/A23260), CRUK trial number CRUKD/16/016, and AstraZeneca through the CRUK’s Combinations Alliance and Experimental Cancer Medicine Centre (ECMC). AstraZeneca provides Selumetinib to participating sites free-of-charge, and was consulted over the trial design but are not involved in the trial management group or safety committee. National Coordinating Centres were supported by a grant from ITCC ‘Imagine for Margo’ fund and AstraZeneca. Staff at the CRCTU are also supported by a core funding grant from Cancer Research UK (C22436/A25354).

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yorkshire &amp; The Humber - Leeds West Research Ethics Committee gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Participant data and the associated supporting documentation will be available within 6 months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director’s Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham’s IT guidance on encryption of data sets.

 [1]: /external-ref?link_type=ISRCTN&amp;access_num=ISRCTN92323261
 [2]: http://ClinicalTrials.Gov
 [3]: /lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT03705507&amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F25%2F2021.10.22.21265327.atom" />
<meta name="og-title" property="og:title" content="Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial" />
<meta name="og-url" property="og:url" content="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" />
<meta name="og-site-name" property="og:site_name" content="medRxiv" />
<meta name="og-description" property="og:description" content="Introduction Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with preclinical data suggesting the combination of dexamethasone with the MEK1/2 inhibitor, selumetinib (ARRY-142886), results in a potent synergistic anti-cancer effect.

Methods and analysis The SeluDex trial is an international, parallel-group, dose-finding with expansion, phase I/II trial to assess the selumetinib/dexamethasone combination in adult and paediatric patients with relapsed/refractory, RAS pathway mutant ALL. The Cancer Research UK Clinical Trials Unit at University of Birmingham is the UK Coordinating Centre, with national hubs in Copenhagen, Denmark; Monza, Italy; Münster, Germany; Paris, France; and Utrecht, Netherlands. Paediatric centres are all part of the Innovative Therapies for Children with Cancer consortium. Patients with morphologically proven relapsed/refractory or progressive B-cell precursor or T-ALL, with demonstrated RAS pathway activating mutations are eligible. Adult patients are ≥18 years old, ECOG ≤2 and paediatric &lt;18 years old, Lansky play scale ≥60% or Karnofsky score ≥60%. The primary objective in phase I is to determine the recommended phase II dose of selumetinib as defined by occurrence/non-occurrence of dose limiting toxicities using the continual reassessment method, and phase II will evaluate preliminary anti-leukaemic activity of the selumetinib/dexamethasone combination, as defined by morphological response 28 days post treatment using a Bayesian approach. Target recruitment is between 26 and 42 patients (minimum of 13 and maximum of 21 in each group), depending on how many phase I patients are included also in phase II.

Ethics and dissemination Medical ethical committees of all the participating countries will approve the study protocol. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.

Trial registration number The trial was registered on EudraCT 2016-003904-29 on 21st September 2016, [ISRCTN 92323261][1], [ClinicalTrials.Gov][2] [NCT03705507][3], and ITCC-063 study.

Strengths and limitations of this study 

### Competing Interest Statement

JI has received research funding from F. Hoffmann-La Roche Ltd. All other authors declare no other relevant conflicts of interest.

### Clinical Trial

NCT03705507

### Funding Statement

This work is supported by Cancer Research UK (C27943/A22304), CRUK trial number CRUKD/16/015 and (C27943/A23260), CRUK trial number CRUKD/16/016, and AstraZeneca through the CRUK’s Combinations Alliance and Experimental Cancer Medicine Centre (ECMC). AstraZeneca provides Selumetinib to participating sites free-of-charge, and was consulted over the trial design but are not involved in the trial management group or safety committee. National Coordinating Centres were supported by a grant from ITCC ‘Imagine for Margo’ fund and AstraZeneca. Staff at the CRCTU are also supported by a core funding grant from Cancer Research UK (C22436/A25354).

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yorkshire &amp; The Humber - Leeds West Research Ethics Committee gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Participant data and the associated supporting documentation will be available within 6 months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director’s Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham’s IT guidance on encryption of data sets.

 [1]: /external-ref?link_type=ISRCTN&amp;access_num=ISRCTN92323261
 [2]: http://ClinicalTrials.Gov
 [3]: /lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT03705507&amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F25%2F2021.10.22.21265327.atom" />
<meta name="og-type" property="og:type" content="article" />
<meta name="og-image" property="og:image" content="" />
<meta name="citation_date" content="2021-10-25" />
<meta name="description" content="medRxiv - The Preprint Server for Health Sciences" />
<meta name="generator" content="Drupal 7 (http://drupal.org)" />
<link rel="canonical" href="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" />
<link rel="shortlink" href="https://www.medrxiv.org/node/426358" />
    <title>Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phas… | medRxiv</title>  
    <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__7SC0i-kTgUlQGKuqbmyS18Sez8FDO-aG9FSHkGrLGl8__9Xf-fJpmF9h8tvWywQTaOzJzFLt4sEfx108Wh1gYmm0__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__6CA0-YpwAeHt1tcr6dmX5ZBUuxlddlGnE8FCmWRwxOw__M2jATP9fgS6Hut-L0G3s312CoMA5SDjnuWFM3KPLIRs__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<style type="text/css" media="all">
/* <![CDATA[ */
#sliding-popup.sliding-popup-bottom,#sliding-popup.sliding-popup-bottom .eu-cookie-withdraw-banner,.eu-cookie-withdraw-tab{background:gray}#sliding-popup.sliding-popup-bottom.eu-cookie-withdraw-wrapper{background:transparent}#sliding-popup .popup-content #popup-text h1,#sliding-popup .popup-content #popup-text h2,#sliding-popup .popup-content #popup-text h3,#sliding-popup .popup-content #popup-text p,.eu-cookie-compliance-secondary-button,.eu-cookie-withdraw-tab{color:#fff !important}.eu-cookie-withdraw-tab{border-color:#fff}.eu-cookie-compliance-more-button{color:#fff !important}
/* ]]> */
</style>

<!--[if lte IE 7]>
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__ElJr3PIJEvw3qLXc1cnYiLj2G4KgDPSXFOfm6Phf8hw__JdWGm15cDWjsK6KrFlQVXQix9YgNeYysf22XZHj-Y-c__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<![endif]-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__Wnlyen9qEpwh_Qaf9okEu4QdVGM0BDothxeqA6Nbvo8__EJmw6SZD9bYoS8jocCpPYS3JFRURpdzmuvJoAUNiI-g__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__XPg6Aobs217v0T9rA_Y-wMrH3jyqmqunImGwMN4WMEE__Nc8_6i0mjd_g-hzHvpxLmo5g2aluEkJf5SXcEKb7YRY__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />

<!--[if (lt IE 9)&(!IEMobile)]>
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__XH6bpcI0f2dImc-p674DLCZtWBGb-QwxJK1YexVGtno__vUceGprdo5nIhV6DH93X7fI3r8RcTJbChbas9TQXeW4__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<![endif]-->

<!--[if gte IE 9]><!-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__2WBMox6sOrN42ss5lCnH7WWVRdFdJCxtTKnQJYRwTE4__yqNvNYLvMpjy3ffuJrjjm9uW2i-Me1c23KLYuWHaqio__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<!--<![endif]-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__GJ_y0JYBjHihOcdJg-wLEQWRfqvBxU74PCdjUcUHlyY__f0nQteVSjWTKq2ga8E2qYttGognShmPZZJdeGhQoNFI__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.css" media="all" />
    <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BKYqkKToQ7EjirB7eIdMEH5521EU3da9IpoOs8Ex2XI__aSjVoX8giBmLhN2EbCgIGQJNu89Mh5aVu1LvI_gkJ7Y__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.js"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__4Cn2dxvNlsJ-sHe6QOTLREaQvcqb0Yh0Zm9tTOHtQow__DGggC5UtYkPCwIH8nsa7Vw7hug93fb9QVVl0UJ3mfMM__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="https://www.google.com/recaptcha/api.js?hl=en&amp;render=explicit&amp;onload=drupalRecaptchaOnload"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__dGWpV57YWu3sX6UOe04RMH-iP9jSkEP7Ajt0caYXZZk__sUEhH4BzLc9Xn679uyzc7yvwgMkxjsks2WFVnFK0PiI__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" async="async" src="https://scholar.google.com/scholar_js/casa.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
/*!
 * yepnope1.5.4
 * (c) WTFPL, GPLv2
 */
(function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i<a.length;i++)j=a[i],e(j)?g(j,0,l,0):w(j)?B(j):Object(j)===j&&h(j,l);else Object(a)===a&&h(a,l)},B.addPrefix=function(a,b){z[a]=b},B.addFilter=function(a){x.push(a)},B.errorTimeout=1e4,null==b.readyState&&b.addEventListener&&(b.readyState="loading",b.addEventListener("DOMContentLoaded",A=function(){b.removeEventListener("DOMContentLoaded",A,0),b.readyState="complete"},0)),a.yepnope=k(),a.yepnope.executeStack=h,a.yepnope.injectJs=function(a,c,d,e,i,j){var k=b.createElement("script"),l,o,e=e||B.errorTimeout;k.src=a;for(o in d)k.setAttribute(o,d[o]);c=j?h:c||f,k.onreadystatechange=k.onload=function(){!l&&g(k.readyState)&&(l=1,c(),k.onload=k.onreadystatechange=null)},m(function(){l||(l=1,c(1))},e),i?k.onload():n.parentNode.insertBefore(k,n)},a.yepnope.injectCss=function(a,c,d,e,g,i){var e=b.createElement("link"),j,c=i?h:c||f;e.href=a,e.rel="stylesheet",e.type="text/css";for(j in d)e.setAttribute(j,d[j]);g||(n.parentNode.insertBefore(e,n),m(c,0))}})(this,document);

//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
yepnope({
  test: Modernizr.matchmedia,
  nope: '/sites/all/libraries/media-match/media.match.min.js'
});
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
var _prum=[['id', '52e95df3abe53d2e33000000'], ['mark', 'firstbyte',
      (new Date()).getTime()]]; (function() {
      var s=document.getElementsByTagName('script')[0],
      p=document.createElement('script');
      p.async='async'; p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
if(typeof window.MathJax === "undefined") window.MathJax = { menuSettings: { zoom: "Click" } };
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
(function(i,s,o,g,r,a,m){i["GoogleAnalyticsObject"]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,"script","//www.google-analytics.com/analytics.js","ga");ga("create", "UA-141606356-1", {"cookieDomain":"auto"});ga("set", "page", location.pathname + location.search + location.hash);ga("send", "pageview");ga('create', 'UA-189672-38', 'auto', {'name': 'hwTracker'});
ga('set', 'anonymizeIp', true);
ga('hwTracker.send', 'pageview');
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"jcore_1","theme_token":"8ybd4TcbT_mmfg44c2LbwGPm_7PBY7FIHJg0-H28ZhY"},"colorbox":{"opacity":"0.85","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","maxWidth":"98%","maxHeight":"98%","fixed":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"highwire":{"nid":"426358","apath":"\/medrxiv\/early\/2021\/10\/25\/2021.10.22.21265327.atom","pisa":"medrxiv;2021.10.22.21265327v1","ac":{"\/medrxiv\/early\/2021\/10\/25\/2021.10.22.21265327.atom":{"access":{"full":true},"pisa_id":"","apath":"\/medrxiv\/early\/2021\/10\/25\/2021.10.22.21265327.atom","jcode":"medrxiv"}},"processed":["highwire_math"],"markup":[{"requested":"abstract","variant":"abstract","view":"abstract","pisa":"medrxiv;2021.10.22.21265327v1"}],"modal_window_width":"560","share_modal_width":"560","share_modal_title":"Share this Article"},"jcarousel":{"ajaxPath":"\/jcarousel\/ajax\/views"},"instances":"{\u0022highwire_abstract_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:20,\u0022height\u0022:20,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-abstract-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022right center\u0022,\u0022my\u0022:\u0022left center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022shift\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter click \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_author_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-author-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022top center\u0022,\u0022my\u0022:\u0022bottom center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_reflinks_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022mimic\u0022:\u0022top center\u0022,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-ref-link-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022bottom left\u0022,\u0022my\u0022:\u0022top left\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022flip\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}}}","qtipDebug":"{\u0022leaveElement\u0022:0}","panel_ajax_tab":{"path":"sites\/all\/modules\/contrib\/panels_ajax_tab"},"disqus":{"domain":"medRxiv","url":"https:\/\/www.medrxiv.org\/content\/10.1101\/2021.10.22.21265327v1","title":"Selumetinib in combination with dexamethasone for the treatment of relapsed\/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phas\u2026","identifier":"node\/426358"},"panels_ajax_pane":{"new-41":"{\u0022encrypted\u0022:\u0022{\\\u0022encrypted\\\u0022:\\\u00220x5zK1rBiNEJQSaeayvJHnaYYhrOX9l\\\\\\\/aWxCpDiizA+guxpdPfY3+qcZF8SUQGmzpOgJHueXDsFjOLP3GR4gxxAO6y2qCVRQi3GP6IlTC1KgkowGMr9F+y111HzdlZmlukhcuLuKZEv4GvOXJvnrv3TQt4eSjPlQ7PnE8+Px7XlVfDUyavy8+pkqenos6g1fi6UhzO4tklsjCDBpAV1e1w2vGFhHoo2W6IUqXBgihk2DEJTnCASlFXVGzD6MRP9yGVXO+56lZSYgVrE8IycmbCFTtJb0o0Cn\\\\\\\/aShI21gv0RzPe8aStZ6QPtBoJS8MILxMrMrhMIWzTtQxzJmAYXUcn4Ah6f3IJadYSenExnQ8y1q4AQYynXZJYbd9JZQb+FFu034FcG3o3sK0e57IbGhrsqzcaSQOlNajxVm0yp3g+VKcOIjgI+Yw0YSDqs4g9WEtlZEEf3YfomqHs22RFKq3UHkBzmfoT7+1R1Ka4BW51T38FBMw+G9zMqlausVcaELp1lFq1E0iNfJZhWeICnRlkQakYLbzN9d4eqkzilZZGs\\\\\\\/zVmWlACkA71LlD81jsWmDIMOrZIfO6ZuVDsCAgcw7incqAVFeZ9b8ObqNAD2i05abKm8VBVGek7b054r0rtDK8A9Vc1AzmcRjUpS7MUzYvhS6geInfLaTpffILBAxDJqAd7sJxM1Qaa4QZWX9TmF5KulSbLT9uheTQXKy\\\\\\\/fec5xJ64WoXtMEftYWIm1OcGmSyud22Q\\\\\\\/pzX4wa3Bkr26vzssPN0Qe7Ejn95RUe4Rd9uxHdFjLlpMaKag9npQjHa9enXa783yqT8s3\\\\\\\/I0ZjdcUOYMzZub\\\\\\\/MssttK1Jrw8eBVsktg67p8YZC+0lga6FVnefZXpxcQ64mbbjLWsh4LqI7O0naoRUrMxXTTuan3JIQrLcZK+ofpBMmS38Nvx1O+OOmayMbhliD9UuzwEWdWwXuNvNHb4E3hCAxxPqGMv02GUiiitDEDp4esGqehYiexw8julnsBvMhnh6m5UcKj2PhyjmfV7gC5z0IunAGUItkReQ+6LhLFvg+JoTVyP8pasEhz7C+91dP9cVvItsY+4lB3LC7K2qmZPa3sSN5wXVKE9CwTwckOVeez3STbvgGFSLm7cTl6iNhiOJmLTiVcjiBRPFU\\\\\\\/wieet9wluFdnaDGZnrA4GvPgVpHoYBL87fgF7GZYx0VTd4BEaq0c3EHzSIJXARgX6DVrKih0isMK8tqD8BvWCjPecYyv+up7AANQAaFYIViDk0ZKOweB4cuOyG\\\u0022,\\\u0022iv\\\u0022:\\\u0022CTGDVjqXWG0RMJo0ak08BQ==\\\u0022,\\\u0022salt\\\u0022:\\\u0022f9d8845712f72c9fee5db7d9ff111eab\\\u0022}\u0022,\u0022hmac\u0022:\u0022bed53a967a81a61cb2eb5dffa5cf09637422d0c0f50f6971441988ec8aa9aef8\u0022}"},"urlIsAjaxTrusted":{"\/content\/10.1101\/2021.10.22.21265327v1":true},"ws_fl":{"width":100,"height":21},"ws_gpo":{"size":"","annotation":"","lang":"","callback":"","width":300},"color":{"logo":"https:\/\/www.medrxiv.org\/sites\/default\/files\/medrxiv_internal_logo.png"},"highwire_list_expand":{"is_collapsed":"1"},"highwireResponsive":{"enquire_enabled":1,"breakpoints_configured":1,"breakpoints":{"zero":"all and (min-width: 0px)","xsmall":"all and (min-width: 380px)","narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}},"eu_cookie_compliance":{"popup_enabled":1,"popup_agreed_enabled":0,"popup_hide_agreed":0,"popup_clicking_confirmation":1,"popup_scrolling_confirmation":false,"popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003EWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","use_mobile_message":false,"mobile_popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n          \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","mobile_breakpoint":"768","popup_html_agreed":"\u003Cdiv\u003E\n  \u003Cdiv class=\u0022popup-content agreed\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Ch2\u003EThank you for accepting cookies\u003C\/h2\u003E\u003Cp\u003EYou can now hide this message or find out more about cookies.\u003C\/p\u003E    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022hide-popup-button eu-cookie-compliance-hide-button\u0022\u003EHide\u003C\/button\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button-thank-you\u0022 \u003EMore info\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","popup_use_bare_css":false,"popup_height":"auto","popup_width":"100%","popup_delay":1000,"popup_link":"\/help\/cookie-policy","popup_link_new_window":1,"popup_position":null,"popup_language":"en","store_consent":false,"better_support_for_screen_readers":0,"reload_page":0,"domain":"","popup_eu_only_js":0,"cookie_lifetime":"365","cookie_session":false,"disagree_do_not_show_popup":0,"method":"default","whitelisted_cookies":"","withdraw_markup":"\u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-tab\u0022\u003EPrivacy settings\u003C\/button\u003E\n\u003Cdiv class=\u0022eu-cookie-withdraw-banner\u0022\u003E\n  \u003Cdiv class=\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003E\u0026lt;h2\u0026gt;We use cookies on this site to enhance your user experience\u0026lt;\/h2\u0026gt;\u0026lt;p\u0026gt;You have given your consent for us to set cookies.\u0026lt;\/p\u0026gt;\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-button\u0022\u003EWithdraw consent\u003C\/button\u003E\n    \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","withdraw_enabled":false},"googleanalytics":{"trackOutbound":1,"trackMailto":1,"trackDownload":1,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip","trackColorbox":1,"trackUrlFragments":1},"jnl_biorxiv_styles":{"defaultJCode":"medrxiv"},"omega":{"layouts":{"primary":"normal","order":["narrow","normal","wide"],"queries":{"narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}}}});
//--><!]]>
</script>
    <!--[if lt IE 9]><script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]-->
  </head>
  <body class="html not-front not-logged-in page-node page-node- page-node-426358 node-type-highwire-article context-content hw-default-jcode-medrxiv hw-article-type-article">
<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-P4HH5NV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script type="text/javascript">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-P4HH5NV');</script>
<!-- End Google Tag Manager -->
    <div id="skip-link">
      <a href="#main-content" class="element-invisible element-focusable">Skip to main content</a>
    </div>
        <div class="page clearfix page-box-shadows footer-borders panels-page panels-layout-jcore_2col" id="page">
      <header id="section-header" class="section section-header">
    
  <div id="zone-branding" class="zone zone-branding clearfix print-display-block container-30">
    <div class="grid-15 prefix-1 region region-branding print-display-block" id="region-branding">
  <div class="region-inner region-branding-inner">
        <div class="branding-data clearfix">
            <div class="logo-img">
        <a href="/" rel="home" class="" data-icon-position="" data-hide-link-title="0"><img alt="medRxiv" src="https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png" /></a>      </div>
                </div>
          </div>
</div><div class="grid-11 suffix-1 region region-branding-second print-hidden" id="region-branding-second">
  <div class="region-inner region-branding-second-inner">
    <div class="block block-system block-menu block-main-menu block-system-main-menu odd block-without-title" id="block-system-main-menu">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf" role="menuitem"><a href="/" title="" class="" data-icon-position="" data-hide-link-title="0">Home</a></li>
<li class="leaf" role="menuitem"><a href="/content/about-medrxiv" class="" data-icon-position="" data-hide-link-title="0">About</a></li>
<li class="leaf" role="menuitem"><a href="/submit-a-manuscript" class="" data-icon-position="" data-hide-link-title="0">Submit</a></li>
<li class="last leaf" role="menuitem"><a href="/content/alertsrss" title="" class="" data-icon-position="" data-hide-link-title="0">ALERTS / RSS</a></li>
</ul></nav>    </div>
  </div>
</div><div class="block block-panels-mini block-biorxiv-search-box block-panels-mini-biorxiv-search-box even block-without-title" id="block-panels-mini-biorxiv-search-box">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_search_box">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-seach-quicksearch" >
  
      
  
  <div class="pane-content">
    <form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/10.1101/2021.10.22.21265327v1" method="post" id="highwire-search-quicksearch-form-0" accept-charset="UTF-8"><div><div class="form-item form-item-label-invisible form-type-textfield form-item-keywords">
  <label class="element-invisible" for="edit-keywords">Search for this keyword </label>
 <input placeholder="Search" type="text" id="edit-keywords" name="keywords" value="" size="60" maxlength="128" class="form-text" />
</div>
<div class="button-wrapper button-mini"><span class="icon-search"></span><input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="edit-submit--2" name="op" value="Search" class="form-submit" /></div><input type="hidden" name="form_build_id" value="form-LHjOxOVYe4cezDtrFkXi8CGkBwEaFOdq6f_kB7j4xLA" />
<input type="hidden" name="form_id" value="highwire_search_quicksearch_form_0" />
</div></form>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-2 advanced-search-link" >
  
      
  
  <div class="pane-content">
    <a href="/search">Advanced Search</a>  </div>

  
  </div>
</div>
  </div>
</div>
    </div>
  </div>
</div>  </div>
</div>  </div>
  
  <div id="zone-header" class="zone zone-header clearfix container-30">
  	      </div>
</header>    
      <section id="section-content" class="section section-content">
    
  <div id="zone-content" class="zone zone-content clearfix container-30">    
        
    <div class="grid-28 suffix-1 prefix-1 region region-content" id="region-content">
  <div class="region-inner region-content-inner">
    <a id="main-content"></a>
                        <div class="block block-system block-main block-system-main odd block-without-title" id="block-system-main">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <div class="panel-display panels-960-layout jcore-2col-layout" >
	  
  <div class="panel-row-wrapper clearfix">
		
		<div class="main-content-wrapper grid-17 suffix-1 alpha">
			<div class="panel-panel panel-region-content">
			  <div class="inside"><div class="panel-pane pane-highwire-article-citation" >
  
      
  
  <div class="pane-content">
    <div class="highwire-article-citation highwire-citation-type-highwire-article node426358" data-node-nid="426358" id="node426358--2481941506" data-pisa="medrxiv;2021.10.22.21265327v1" data-pisa-master="medrxiv;2021.10.22.21265327" data-apath="/medrxiv/early/2021/10/25/2021.10.22.21265327.atom" data-hw-author-tooltip-instance=""><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-medrxiv-article-top clearfix has-author-tooltip" >

  
      <h1 class="highwire-cite-title" id="page-title">Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial</h1>  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">Tobias</span> <span class="nlm-surname">Menne</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Daniel</span> <span class="nlm-surname">Slade</span></span>, <span class="highwire-citation-author hw-author-orcid-logo-wrapper" data-delta="2"><a href="http://orcid.org/0000-0003-0599-0245" target="_blank" class="hw-author-orcid-logo link-icon-only link-icon"><span class="hw-icon-orcid hw-icon-color-orcid"></span> <span class="title element-invisible">View ORCID Profile</span></a><span class="nlm-given-names">Joshua</span> <span class="nlm-surname">Savage</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Sarah</span> <span class="nlm-surname">Johnson</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">Julie</span> <span class="nlm-surname">Irving</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Pamela R.</span> <span class="nlm-surname">Kearns</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Ruth</span> <span class="nlm-surname">Plummer</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Geoff</span> <span class="nlm-surname">Shenton</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Gareth J.</span> <span class="nlm-surname">Veal</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Britta</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">Josef</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author hw-author-orcid-logo-wrapper" data-delta="11"><a href="http://orcid.org/0000-0001-8581-4262" target="_blank" class="hw-author-orcid-logo link-icon-only link-icon"><span class="hw-icon-orcid hw-icon-color-orcid"></span> <span class="title element-invisible">View ORCID Profile</span></a><span class="nlm-given-names">Lucinda</span> <span class="nlm-surname">Billingham</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="label">doi:</span> https://doi.org/10.1101/2021.10.22.21265327 </span></div>
  
  
  
</div>
<div id="hw-article-author-popups-node426358--2481941506" style="display: none;"><div class="author-tooltip-0"><div class="author-tooltip-name">Tobias Menne </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust</span>, Newcastle upon Tyne. NE7 7DN. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Tobias%2BMenne%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Menne%20T&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ATobias%2BMenne%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-1"><div class="author-tooltip-name">Daniel Slade </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham</span>, Edgbaston, Birmingham. B15 2TT. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Daniel%2BSlade%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Slade%20D&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ADaniel%2BSlade%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-2"><div class="author-tooltip-name">Joshua Savage </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham</span>, Edgbaston, Birmingham. B15 2TT. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Joshua%2BSavage%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Savage%20J&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link"><a href="/search/author1%3AJoshua%2BSavage%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li><li class="author-orcid-link last"><a href="http://orcid.org/0000-0003-0599-0245" target="_blank" class="" data-icon-position="" data-hide-link-title="0">ORCID record for Joshua Savage</a></li></ul></div><div class="author-tooltip-3"><div class="author-tooltip-name">Sarah Johnson </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham</span>, Edgbaston, Birmingham. B15 2TT. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Sarah%2BJohnson%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Johnson%20S&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ASarah%2BJohnson%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-4"><div class="author-tooltip-name">Julie Irving </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>3</span><span class='nlm-institution'>Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University</span>, Newcastle upon Tyne. NE1 7RU. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Julie%2BIrving%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Irving%20J&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AJulie%2BIrving%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-5"><div class="author-tooltip-name">Pamela R. Kearns </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham</span>, Edgbaston, Birmingham. B15 2TT. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Pamela%2BR.%2BKearns%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Kearns%20PR&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3APamela%2BR.%2BKearns%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-6"><div class="author-tooltip-name">Ruth Plummer </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust</span>, Newcastle upon Tyne. NE7 7DN. <span class='nlm-country'>UK</span></div><div class='author-affiliation'><span class='nlm-sup'>3</span><span class='nlm-institution'>Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University</span>, Newcastle upon Tyne. NE1 7RU. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Ruth%2BPlummer%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Plummer%20R&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ARuth%2BPlummer%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-7"><div class="author-tooltip-name">Geoff Shenton </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>4</span><span class='nlm-institution'>Great North Children’s Hospital, Royal Victoria Infirmary Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust</span>, Newcastle upon Tyne. NE7 7DN. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Geoff%2BShenton%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Shenton%20G&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AGeoff%2BShenton%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-8"><div class="author-tooltip-name">Gareth J. Veal </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>3</span><span class='nlm-institution'>Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University</span>, Newcastle upon Tyne. NE1 7RU. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Gareth%2BJ.%2BVeal%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Veal%20GJ&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AGareth%2BJ.%2BVeal%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-9"><div class="author-tooltip-name">Britta Vormoor </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>5</span><span class='nlm-institution'>Princess Máxima Center for Paediatric Oncology</span>, Heidelberglaan 25, 3584CS Utrecht. <span class='nlm-country'>The Netherlands</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Britta%2BVormoor%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Vormoor%20B&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ABritta%2BVormoor%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-10"><div class="author-tooltip-name">Josef Vormoor </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>3</span><span class='nlm-institution'>Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University</span>, Newcastle upon Tyne. NE1 7RU. <span class='nlm-country'>UK</span></div><div class='author-affiliation'><span class='nlm-sup'>5</span><span class='nlm-institution'>Princess Máxima Center for Paediatric Oncology</span>, Heidelberglaan 25, 3584CS Utrecht. <span class='nlm-country'>The Netherlands</span></div><div class='author-affiliation'><span class='nlm-sup'>6</span><span class='nlm-institution'>University Medical Center</span>, Utrecht, Heidelberglaan 100, 3584CX Utrecht. <span class='nlm-country'>The Netherlands</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Josef%2BVormoor%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Vormoor%20J&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AJosef%2BVormoor%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-11"><div class="author-tooltip-name">Lucinda Billingham </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust</span>, Newcastle upon Tyne. NE7 7DN. <span class='nlm-country'>UK</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Lucinda%2BBillingham%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Billingham%20L&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link"><a href="/search/author1%3ALucinda%2BBillingham%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li><li class="author-orcid-link"><a href="http://orcid.org/0000-0001-8581-4262" target="_blank" class="" data-icon-position="" data-hide-link-title="0">ORCID record for Lucinda Billingham</a></li><li class="author-corresp-email-link last"><span>For correspondence: 
<a href="mailto:L.J.Billingham@bham.ac.uk" class="" data-icon-position="" data-hide-link-title="0">L.J.Billingham@bham.ac.uk</a></span></li></ul></div></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs" >
  
      
  
  <div class="pane-content">
    <div class="item-list"><ul class="tabs inline panels-ajax-tab"><li class="first"><a href="/content/10.1101/2021.10.22.21265327v1" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="" data-url-enabled="1">Abstract</a><a href="/panels_ajax_tab/biorxiv_tab_art/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.22.21265327v1.full-text" class="panels-ajax-tab-tab" data-panel-name="article_tab_full_text" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="full-text" data-url-enabled="1">Full Text</a><a href="/panels_ajax_tab/article_tab_full_text/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.22.21265327v1.article-info" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="article-info" data-url-enabled="1">Info/History</a><a href="/panels_ajax_tab/biorxiv_tab_info/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.22.21265327v1.article-metrics" class="panels-ajax-tab-tab" data-panel-name="article_tab_metrics" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="article-metrics" data-url-enabled="1">Metrics</a><a href="/panels_ajax_tab/article_tab_metrics/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.22.21265327v1.supplementary-material" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_data" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="supplementary-material" data-url-enabled="1">Supplementary material</a><a href="/panels_ajax_tab/biorxiv_tab_data/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.22.21265327v1.external-links" class="panels-ajax-tab-tab" data-panel-name="article_tab_data_code" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="external-links" data-url-enabled="1">Data/Code</a><a href="/panels_ajax_tab/article_tab_data_code/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li class="last"><a href="/content/10.1101/2021.10.22.21265327v1.full.pdf+html" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_pdf" data-target-id="highwire_article_tabs" data-entity-context="node:426358" data-trigger="full.pdf+html" data-url-enabled="1"><i class="icon-file-alt"></i> Preview PDF</a><a href="/panels_ajax_tab/biorxiv_tab_pdf/node:426358/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li></ul></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs-container" >
  
      
  
  <div class="pane-content">
    <div data-panels-ajax-tab-preloaded="biorxiv_tab_art" id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container"><div class="panels-ajax-tab-loading" style ="display:none"><img class="loading" src="https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading" /></div><div class="panels-ajax-tab-wrap-biorxiv_tab_art"><div class="panel-display panel-1col clearfix" >
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-markup" >
  
      
  
  <div class="pane-content">
    <div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" class="content-block-markup" xmlns:xhtml="http://www.w3.org/1999/xhtml"><div class="article abstract-view "><span class="highwire-journal-article-marker-start"></span><div class="section abstract" id="abstract-1"><h2 class="">Abstract</h2><div id="sec-1" class="subsection"><p id="p-4"><strong>Introduction</strong> Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with preclinical data suggesting the combination of dexamethasone with the MEK1/2 inhibitor, selumetinib (ARRY-142886), results in a potent synergistic anti-cancer effect.</p></div><div id="sec-2" class="subsection"><p id="p-5"><strong>Methods and analysis</strong> The SeluDex trial is an international, parallel-group, dose-finding with expansion, phase I/II trial to assess the selumetinib/dexamethasone combination in adult and paediatric patients with relapsed/refractory, RAS pathway mutant ALL. The Cancer Research UK Clinical Trials Unit at University of Birmingham is the UK Coordinating Centre, with national hubs in Copenhagen, Denmark; Monza, Italy; Münster, Germany; Paris, France; and Utrecht, Netherlands. Paediatric centres are all part of the Innovative Therapies for Children with Cancer consortium. Patients with morphologically proven relapsed/refractory or progressive B-cell precursor or T-ALL, with demonstrated RAS pathway activating mutations are eligible. Adult patients are ≥18 years old, ECOG ≤2 and paediatric &lt;18 years old, Lansky play scale ≥60% or Karnofsky score ≥60%. The primary objective in phase I is to determine the recommended phase II dose of selumetinib as defined by occurrence/non-occurrence of dose limiting toxicities using the continual reassessment method, and phase II will evaluate preliminary anti-leukaemic activity of the selumetinib/dexamethasone combination, as defined by morphological response 28 days post treatment using a Bayesian approach. Target recruitment is between 26 and 42 patients (minimum of 13 and maximum of 21 in each group), depending on how many phase I patients are included also in phase II.</p></div><div id="sec-3" class="subsection"><p id="p-6"><strong>Ethics and dissemination</strong> Medical ethical committees of all the participating countries will approve the study protocol. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.</p></div><div id="sec-4" class="subsection"><p id="p-7"><strong>Trial registration number</strong> The trial was registered on EudraCT 2016-003904-29 on 21<sup>st</sup> September 2016, <a href="/external-ref?link_type=ISRCTN&amp;access_num=ISRCTN92323261" class="external-ref external-ref-type-isrctn">ISRCTN 92323261</a>, <a href="http://ClinicalTrials.Gov">ClinicalTrials.Gov</a> <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT03705507&amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F25%2F2021.10.22.21265327.atom">NCT03705507</a>, and ITCC-063 study.</p></div><div id="sec-5" class="subsection"><p><strong>Strengths and limitations of this study</strong></p><ul class="list-unord " id="list-1"><li id="list-item-1"><p id="p-8">Novel combination of the MEK1/2 inhibitor, selumetinib, with dexamethasone</p></li><li id="list-item-2"><p id="p-9">Seamless phase I/II Bayesian trial design with a Continual Reassessment Method for dose escalation in phase I</p></li><li id="list-item-3"><p id="p-10">Parallel cohort trial design of adult and paediatric patients within one protocol</p></li><li id="list-item-4"><p id="p-11">Availability of CAR T-cell therapy since this trial started recruitment has competed for the same patient population</p></li><li id="list-item-5"><p id="p-12">Offers a bridging treatment option for patients awaiting CAR T-cell therapy outside clinical studies or at relapse after CAR-T treatment</p></li></ul></div></div><h3>Competing Interest Statement</h3><p id="p-13">JI has received research funding from F. Hoffmann-La Roche Ltd. All other authors declare no other relevant conflicts of interest.</p><h3>Clinical Trial</h3><p id="p-14">NCT03705507</p><h3>Funding Statement</h3><p id="p-15">This work is supported by Cancer Research UK (C27943/A22304), CRUK trial number CRUKD/16/015 and (C27943/A23260), CRUK trial number CRUKD/16/016, and AstraZeneca through the CRUK’s Combinations Alliance and Experimental Cancer Medicine Centre (ECMC). AstraZeneca provides Selumetinib to participating sites free-of-charge, and was consulted over the trial design but are not involved in the trial management group or safety committee. National Coordinating Centres were supported by a grant from ITCC ‘Imagine for Margo’ fund and AstraZeneca. Staff at the CRCTU are also supported by a core funding grant from Cancer Research UK (C22436/A25354).</p><h3>Author Declarations</h3><p id="p-16">I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p id="p-17">Yes</p><p id="p-18">The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p id="p-19">Yorkshire &amp; The Humber - Leeds West Research Ethics Committee gave ethical approval for this work.</p><p id="p-20">I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.</p><p id="p-21">Yes</p><p id="p-22">I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p id="p-23">Yes</p><p id="p-24">I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p id="p-25">Yes</p><div class="section data-availability" id="sec-42"><h2 class="">Data Availability</h2><p id="p-102">Participant data and the associated supporting documentation will be available within 6 months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director’s Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham’s IT guidance on encryption of data sets.</p></div><span class="highwire-journal-article-marker-end"></span></div><span class="related-urls"></span></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-biorxiv-copyright" >
  
      
  
  <div class="pane-content">
    <div class="field field-name-field-highwire-copyright field-type-text field-label-inline clearfix"><div class="field-label">Copyright&nbsp;</div><div class="field-items"><div class="field-item even">The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.<span class="license-type"> It is made available under a <a href="http://creativecommons.org/licenses/by/4.0/" class="" data-icon-position="" data-hide-link-title="0">CC-BY 4.0 International license</a>.</span></div></div></div>  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-disqus-comment" >
  
      
  
  <div class="pane-content">
    <div id="disqus_thread"><noscript><p><a href="http://medRxiv.disqus.com/?url=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2021.10.22.21265327v1" class="" data-icon-position="" data-hide-link-title="0">View the discussion thread.</a></p></noscript></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-back-to-top" >
  
      
  
  <div class="pane-content">
    <a href="#page" class="back-to-top" data-icon-position="" data-hide-link-title="0"><span class="icon-chevron-up"></span> Back to top</a>  </div>

  
  </div>
</div>
			</div>
		</div>
		
		<div class="sidebar-right-wrapper grid-10 omega">
			<div class="panel-panel panel-region-sidebar-right">
			  <div class="inside"><div class="panel-pane pane-highwire-node-pager" >
  
      
  
  <div class="pane-content">
    <div class="pager highwire-pager pager-mini clearfix highwire-node-pager highwire-article-pager"><span class="pager-prev"><a href="/content/10.1101/2021.10.21.21265356v1" title="Household contact tracing with intensified tuberculosis and HIV screening in South Africa: a cluster randomised trial" rel="prev" class="pager-link-prev link-icon"><span class="icon-circle-arrow-left"></span> <span class="title">Previous</span></a></span><span class="pager-next"><a href="/content/10.1101/2021.10.21.21265355v1" title="COVID-19 Vaccination Mandates and Vaccine Uptake" rel="next" class="pager-link-next link-icon-right link-icon"><span class="title">Next</span> <span class="icon-circle-arrow-right"></span></a></span></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-1" >
  
      
  
  <div class="pane-content">
    Posted&nbsp;October 25, 2021.  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-art-tools" >
  
      
  
  <div class="pane-content">
    <div id="mini-panel-biorxiv_art_tools" class="highwire-2col-stacked panel-display">
	  
  <div class="panel-row-wrapper clearfix">
		<div class="content-left-wrapper content-column">
          <div class="panel-panel panel-region-content-left">
            <div class="inside"><div class="panel-pane pane-highwire-variant-link" >
  
      
  
  <div class="pane-content">
    <a href="/content/10.1101/2021.10.22.21265327v1.full.pdf" target="_self" class="article-dl-pdf-link link-icon"><span class="icon-external-link-sign"></span> <span class="title">Download PDF</span></a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-biorxiv-supplementary-fragment" >
  
      
  
  <div class="pane-content">
    <p><a href="/content/10.1101/2021.10.22.21265327v1.supplementary-material"><i class="icon-file"></i>Supplementary Material </a></p>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-variant-link" >
  
      
  
  <div class="pane-content">
    <a href="/content/early/2021/10/25/2021.10.22.21265327.external-links" target="_self" class="link-icon"><span class="icon-file"></span> <span class="title">Data/Code</span></a>  </div>

  
  </div>
</div>
          </div>
        </div>
        
        <div class="content-right-wrapper content-column">
          <div class="panel-panel panel-region-content-right">
            <div class="inside"><div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-art-email" >
  
      
  
  <div class="pane-content">
    <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger" title="Email this Article" data-icon-position="" data-hide-link-title="0"><i class = 'icon-envelope'></i> Email</a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_art_email">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-block pane-forward-form pane-forward" >
  
      
  
  <div class="pane-content">
    <form action="/content/10.1101/2021.10.22.21265327v1" method="post" id="forward-form" accept-charset="UTF-8"><div><div id="edit-instructions" class="form-item form-item-label-before form-type-item">
 <p>Thank you for your interest in spreading the word about medRxiv.</p><p>NOTE: Your email address is requested solely to identify you as the sender of this article.</p>
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-email">
  <label for="edit-email">Your Email <span class="form-required" title="This field is required.">*</span></label>
 <input type="text" id="edit-email" name="email" value="" size="58" maxlength="256" class="form-text required" />
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-name">
  <label for="edit-name">Your Name <span class="form-required" title="This field is required.">*</span></label>
 <input type="text" id="edit-name" name="name" value="" size="58" maxlength="256" class="form-text required" />
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-recipients">
  <label for="edit-recipients">Send To <span class="form-required" title="This field is required.">*</span></label>
 <div class="form-textarea-wrapper resizable"><textarea id="edit-recipients" name="recipients" cols="50" rows="5" class="form-textarea required"></textarea></div>
<div class="description">Enter multiple addresses on separate lines or separate them with commas.</div>
</div>
<div id="edit-page" class="form-item form-item-label-before form-type-item">
  <label for="edit-page">You are going to email the following </label>
 <a href="/content/10.1101/2021.10.22.21265327v1" class="active" data-icon-position="" data-hide-link-title="0">Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phas…</a>
</div>
<div id="edit-subject" class="form-item form-item-label-before form-type-item">
  <label for="edit-subject">Message Subject </label>
 (Your Name) has forwarded a page to you from medRxiv
</div>
<div id="edit-body" class="form-item form-item-label-before form-type-item">
  <label for="edit-body">Message Body </label>
 (Your Name) thought you would like to see this page from the medRxiv website.
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-message">
  <label for="edit-message--2">Your Personal Message </label>
 <div class="form-textarea-wrapper resizable"><textarea id="edit-message--2" name="message" cols="50" rows="10" class="form-textarea"></textarea></div>
</div>
<input type="hidden" name="path" value="node/426358" />
<input type="hidden" name="path_cid" value="" />
<input type="hidden" name="forward_footer" value=" " />
<input type="hidden" name="form_build_id" value="form-Zj4QImPCRLyEs9IzdE9ciKgIDAmL_ylElyEmROPfzm8" />
<input type="hidden" name="form_id" value="forward_form" />
<fieldset class="captcha form-wrapper"><legend><span class="fieldset-legend">CAPTCHA</span></legend><div class="fieldset-wrapper"><div class="fieldset-description">This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.</div><input type="hidden" name="captcha_sid" value="157700048" />
<input type="hidden" name="captcha_token" value="f6dfedf053d723b2f7697c59a026fd66" />
<input type="hidden" name="captcha_response" value="Google no captcha" />
<div class="g-recaptcha" data-sitekey="6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN" data-theme="light" data-type="image"></div></div></fieldset>
<div class="form-actions form-wrapper" id="edit-actions"><input type="submit" id="edit-submit" name="op" value="Send Message" class="form-submit" /></div></div></form>  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-share-link highwire_clipboard_link_ajax"  id="shareit">
  
      
  
  <div class="pane-content">
    <a href="/" class="link-icon"><span class="icon-share-alt"></span> <span class="title">Share</span></a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-share highwire_clipboard_form_ajax_shareit" >
  
      
  
  <div class="pane-content">
    
<div class="panel-display omega-12-onecol" id="mini-panel-biorxiv_share">

		  <div class="panel-panel grid-12 panel-region-preface">
		  <div class="inside"><div class="panel-pane pane-highwire-article-citation" >
  
      
  
  <div class="pane-content">
    <div class="highwire-article-citation highwire-citation-type-highwire-article node426358--3" data-node-nid="426358" id="node426358--41788806774" data-pisa="medrxiv;2021.10.22.21265327v1" data-pisa-master="medrxiv;2021.10.22.21265327" data-seqnum="426358" data-apath="/medrxiv/early/2021/10/25/2021.10.22.21265327.atom"><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix" >

      <div class="highwire-cite-title" >
      <div class="highwire-cite-title">Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial</div>    </div>
  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">Tobias</span> <span class="nlm-surname">Menne</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Daniel</span> <span class="nlm-surname">Slade</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">Joshua</span> <span class="nlm-surname">Savage</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Sarah</span> <span class="nlm-surname">Johnson</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">Julie</span> <span class="nlm-surname">Irving</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Pamela R.</span> <span class="nlm-surname">Kearns</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Ruth</span> <span class="nlm-surname">Plummer</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Geoff</span> <span class="nlm-surname">Shenton</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Gareth J.</span> <span class="nlm-surname">Veal</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Britta</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">Josef</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author" data-delta="11"><span class="nlm-given-names">Lucinda</span> <span class="nlm-surname">Billingham</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-journal highwire-cite-metadata">medRxiv </span><span  class="highwire-cite-metadata-pages highwire-cite-metadata">2021.10.22.21265327; </span><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="doi_label">doi:</span> https://doi.org/10.1101/2021.10.22.21265327 </span></div>
  
  
  </div>
</div>  </div>

  
  </div>
</div>
	  </div>
	
  <div class="panel-panel grid-12 panel-region-content">
  	<div class="inside"><div class="panel-pane pane-highwire-article-clipboard-copy" >
  
      
  
  <div class="pane-content">
    <div class = "clipboard-copy">
  <span class="label-url">
    <label for="dynamic">Share This Article:</label>
  </span>
  <span class="input-text-url">
    <input type="text" id="dynamic" value="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" size="50"/>
  </span>
  <span class="copy-button button">
    <button id="copy-dynamic" class="clipboardjs-button" data-clipboard-target="#dynamic" data-clipboard-alert-style="tooltip" data-clipboard-alert-text="Copied!">Copy</button>
  </span>
</div>
  </div>

  
  </div>
</div>
  </div>
	
		  <div class="panel-panel grid-12 panel-region-postscript">
	    <div class="inside"><div class="panel-pane pane-service-links" >
  
      
  
  <div class="pane-content">
    <div class="service-links"><a href="http://digg.com/submit?phase=2&amp;url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;title=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="digg" title="Digg this post on digg.com" class="service-links-digg" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/digg.png" alt="Digg logo" /></a> <a href="http://reddit.com/submit?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;title=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="reddit" title="Submit this post on reddit.com" class="service-links-reddit" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/reddit.png" alt="Reddit logo" /></a> <a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;text=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="twitter" title="Share this on Twitter" class="service-links-twitter" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png" alt="Twitter logo" /></a> <a href="http://www.citeulike.org/posturl?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;title=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="citeulike" title="Share on CiteULike" class="service-links-citeulike" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/citeyoulike.png" alt="CiteULike logo" /></a> <a href="http://www.facebook.com/sharer.php?u=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;t=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="facebook" title="Share on Facebook" class="service-links-facebook" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png" alt="Facebook logo" /></a> <a href="http://www.google.com/bookmarks/mark?op=add&amp;bkmk=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;title=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="google" title="Bookmark this post on Google" class="service-links-google" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/google-32.png" alt="Google logo" /></a> <a href="http://www.mendeley.com/import/?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;title=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6" id="mendeley" title="Share on Mendeley" class="service-links-mendeley" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png" alt="Mendeley logo" /></a></div>  </div>

  
  </div>
</div>
	  </div>
	
</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-cite-tool" >
  
      
  
  <div class="pane-content">
    <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Citation Tools"><span class="icon-globe"></span> <span class="title">Citation Tools</span></a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_cite_tool">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-citation-export" >
  
      
  
  <div class="pane-content">
    <div class="highwire-citation-export">  
  <div class="highwire-citation-info">
      <div class="highwire-article-citation highwire-citation-type-highwire-article node426358--5" data-node-nid="426358" id="node426358--6564350237" data-pisa="medrxiv;2021.10.22.21265327v1" data-pisa-master="medrxiv;2021.10.22.21265327" data-seqnum="426358" data-apath="/medrxiv/early/2021/10/25/2021.10.22.21265327.atom"><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix" >

      <div class="highwire-cite-title" >
      <div class="highwire-cite-title">Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial</div>    </div>
  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">Tobias</span> <span class="nlm-surname">Menne</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Daniel</span> <span class="nlm-surname">Slade</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">Joshua</span> <span class="nlm-surname">Savage</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Sarah</span> <span class="nlm-surname">Johnson</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">Julie</span> <span class="nlm-surname">Irving</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Pamela R.</span> <span class="nlm-surname">Kearns</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Ruth</span> <span class="nlm-surname">Plummer</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Geoff</span> <span class="nlm-surname">Shenton</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Gareth J.</span> <span class="nlm-surname">Veal</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Britta</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">Josef</span> <span class="nlm-surname">Vormoor</span></span>, <span class="highwire-citation-author" data-delta="11"><span class="nlm-given-names">Lucinda</span> <span class="nlm-surname">Billingham</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-journal highwire-cite-metadata">medRxiv </span><span  class="highwire-cite-metadata-pages highwire-cite-metadata">2021.10.22.21265327; </span><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="doi_label">doi:</span> https://doi.org/10.1101/2021.10.22.21265327 </span></div>
  
  
  </div>
</div>  </div>
  <div class="highwire-citation-formats">
  	      <h2>Citation Manager Formats</h2>
        <div class="highwire-citation-formats-links">
      <span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.spage&amp;rft.epage&amp;rft.atitle=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6&amp;rft.volume&amp;rft.issue&amp;rft.date=2021-01-01%2000%3A00%3A00&amp;rft.stitle&amp;rft.jtitle=medRxiv&amp;rft.au=Menne%2C+Tobias&amp;rft.au=Slade%2C+Daniel&amp;rft.au=Savage%2C+Joshua&amp;rft.au=Johnson%2C+Sarah&amp;rft.au=Irving%2C+Julie&amp;rft.au=Kearns%2C+Pamela+R.&amp;rft.au=Plummer%2C+Ruth&amp;rft.au=Shenton%2C+Geoff&amp;rft.au=Veal%2C+Gareth+J.&amp;rft.au=Vormoor%2C+Britta&amp;rft.au=Vormoor%2C+Josef&amp;rft.au=Billingham%2C+Lucinda"></span><ul class="hw-citation-links inline button button-alt button-grid clearfix"><li class="bibtext first"><a href="/highwire/citation/426358/bibtext" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">BibTeX</a></li><li class="bookends"><a href="/highwire/citation/426358/bookends" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Bookends</a></li><li class="easybib"><a href="/highwire/citation/426358/easybib" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EasyBib</a></li><li class="endnote-tagged"><a href="/highwire/citation/426358/endnote-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote (tagged)</a></li><li class="endnote-8-xml"><a href="/highwire/citation/426358/endnote-8-xml" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote 8 (xml)</a></li><li class="medlars"><a href="/highwire/citation/426358/medlars" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Medlars</a></li><li class="mendeley"><a href="/highwire/citation/426358/mendeley" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Mendeley</a></li><li class="papers"><a href="/highwire/citation/426358/papers" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Papers</a></li><li class="refworks-tagged"><a href="/highwire/citation/426358/refworks-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RefWorks Tagged</a></li><li class="reference-manager"><a href="/highwire/citation/426358/reference-manager" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Ref Manager</a></li><li class="ris"><a href="/highwire/citation/426358/ris" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RIS</a></li><li class="zotero last"><a href="/highwire/citation/426358/zotero" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Zotero</a></li></ul>    </div>
  </div>
</div>
  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
</div>
          </div>
        </div>
	</div> <!-- /.panel-row-wrapper -->	
	
	</div>

  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-service-links" >
  
      
  
  <div class="pane-content">
    <div class="service-links"><div class="item-list"><ul><li class="first"><a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;count=horizontal&amp;via=&amp;text=Selumetinib%20in%20combination%20with%20dexamethasone%20for%20the%20treatment%20of%20relapsed/refractory%20RAS-pathway%20mutated%20paediatric%20and%20adult%20acute%20lymphoblastic%20leukaemia%20%28SeluDex%29%3A%20study%20protocol%20for%20an%20international%2C%20parallel-group%2C%20dose-finding%20with%20expansion%20phas%E2%80%A6&amp;counturl=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" class="twitter-share-button service-links-twitter-widget" id="twitter_widget" title="Tweet This" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Tweet Widget</span></a></li><li><a href="http://www.facebook.com/plugins/like.php?href=https%3A//www.medrxiv.org/content/10.1101/2021.10.22.21265327v1&amp;layout=button_count&amp;show_faces=false&amp;action=like&amp;colorscheme=light&amp;width=100&amp;height=21&amp;font=&amp;locale=" id="facebook_like" title="I Like it" class="service-links-facebook-like" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Facebook Like</span></a></li><li class="last"><a href="https://www.medrxiv.org/content/10.1101/2021.10.22.21265327v1" id="google_plus_one" title="Plus it" class="service-links-google-plus-one" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Google Plus One</span></a></li></ul></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-article-collections" >
  
        <h2 class="pane-title">Subject Area</h2>
    
  
  <div class="pane-content">
    <div class="highwire-list-wrapper highwire-article-collections"><div class="highwire-list"><ul class="highwire-article-collection-term-list"><li class="first last odd"><span class="highwire-article-collection-term"><a href="/collection/oncology" class="highlight" data-icon-position="" data-hide-link-title="0">Oncology<i class="icon-caret-right"></i>
</a></span></li></ul></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-subject-collections block-style-col2" >
  
      
  
  <div class="pane-content">
    <div class="panel-flexible panels-flexible-8 clearfix" id="mini-panel-biorxiv_subject_collections">
<div class="panel-flexible-inside panels-flexible-8-inside">
<div class="panels-flexible-region panels-flexible-region-8-center panels-flexible-region-first panels-flexible-region-last">
  <div class="inside panels-flexible-region-inside panels-flexible-region-8-center-inside panels-flexible-region-inside-first panels-flexible-region-inside-last">
<div class="panel-pane pane-snippet" >
  
      
  
  <div class="pane-content">
    <div class="snippet biorxiv-subject-areas-table-title" id="biorxiv-subject-areas-table-title">
  
      
  <div class="snippet-content">
    <b>Subject Areas</b>  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet" >
  
      
  
  <div class="pane-content">
    <div class="snippet biorxiv-subject-areas-view-papers" id="biorxiv-subject-areas-view-papers">
  
      
  <div class="snippet-content">
    <a href="/content/early/recent"><strong>All Articles</strong></a>  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-subject-collections" >
  
      
  
  <div class="pane-content">
    <ul id="collection" class="collection highwire-list-expand"><li class="outer collection depth-2  child first"><div class = "data-wrapper"><a href="/collection/addiction-medicine" class="" data-icon-position="" data-hide-link-title="0">Addiction Medicine</a> <span class = "article-count">(111)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/allergy-and-immunology" class="" data-icon-position="" data-hide-link-title="0">Allergy and Immunology</a> <span class = "article-count">(299)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/anesthesia" class="" data-icon-position="" data-hide-link-title="0">Anesthesia</a> <span class = "article-count">(75)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/cardiovascular-medicine" class="" data-icon-position="" data-hide-link-title="0">Cardiovascular Medicine</a> <span class = "article-count">(665)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/dentistry-and-oral-medicine" class="" data-icon-position="" data-hide-link-title="0">Dentistry and Oral Medicine</a> <span class = "article-count">(121)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/dermatology" class="" data-icon-position="" data-hide-link-title="0">Dermatology</a> <span class = "article-count">(77)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/emergency-medicine" class="" data-icon-position="" data-hide-link-title="0">Emergency Medicine</a> <span class = "article-count">(216)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease" class="" data-icon-position="" data-hide-link-title="0">Endocrinology (including Diabetes Mellitus and Metabolic Disease)</a> <span class = "article-count">(299)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/epidemiology" class="" data-icon-position="" data-hide-link-title="0">Epidemiology</a> <span class = "article-count">(7268)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/forensic-medicine" class="" data-icon-position="" data-hide-link-title="0">Forensic Medicine</a> <span class = "article-count">(4)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/gastroenterology" class="" data-icon-position="" data-hide-link-title="0">Gastroenterology</a> <span class = "article-count">(306)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/genetic-and-genomic-medicine" class="" data-icon-position="" data-hide-link-title="0">Genetic and Genomic Medicine</a> <span class = "article-count">(1295)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/geriatric-medicine" class="" data-icon-position="" data-hide-link-title="0">Geriatric Medicine</a> <span class = "article-count">(126)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-economics" class="" data-icon-position="" data-hide-link-title="0">Health Economics</a> <span class = "article-count">(308)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-informatics" class="" data-icon-position="" data-hide-link-title="0">Health Informatics</a> <span class = "article-count">(1004)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-policy" class="" data-icon-position="" data-hide-link-title="0">Health Policy</a> <span class = "article-count">(526)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-systems-and-quality-improvement" class="" data-icon-position="" data-hide-link-title="0">Health Systems and Quality Improvement</a> <span class = "article-count">(359)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/hematology" class="" data-icon-position="" data-hide-link-title="0">Hematology</a> <span class = "article-count">(151)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/hiv-aids" class="" data-icon-position="" data-hide-link-title="0">HIV/AIDS</a> <span class = "article-count">(287)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/infectious_diseases" class="" data-icon-position="" data-hide-link-title="0">Infectious Diseases (except HIV/AIDS)</a> <span class = "article-count">(8512)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/intensive-care-and-critical-care-medicine" class="" data-icon-position="" data-hide-link-title="0">Intensive Care and Critical Care Medicine</a> <span class = "article-count">(483)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/medical-education" class="" data-icon-position="" data-hide-link-title="0">Medical Education</a> <span class = "article-count">(160)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/medical-ethics" class="" data-icon-position="" data-hide-link-title="0">Medical Ethics</a> <span class = "article-count">(40)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nephrology" class="" data-icon-position="" data-hide-link-title="0">Nephrology</a> <span class = "article-count">(153)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/neurology" class="" data-icon-position="" data-hide-link-title="0">Neurology</a> <span class = "article-count">(1239)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nursing" class="" data-icon-position="" data-hide-link-title="0">Nursing</a> <span class = "article-count">(63)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nutrition" class="" data-icon-position="" data-hide-link-title="0">Nutrition</a> <span class = "article-count">(200)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/obstetrics-and-gynecology" class="" data-icon-position="" data-hide-link-title="0">Obstetrics and Gynecology</a> <span class = "article-count">(255)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/occupational-and-environmental-health" class="" data-icon-position="" data-hide-link-title="0">Occupational and Environmental Health</a> <span class = "article-count">(368)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/oncology" class="" data-icon-position="" data-hide-link-title="0">Oncology</a> <span class = "article-count">(702)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/ophthalmology" class="" data-icon-position="" data-hide-link-title="0">Ophthalmology</a> <span class = "article-count">(217)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/orthopedics" class="" data-icon-position="" data-hide-link-title="0">Orthopedics</a> <span class = "article-count">(70)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/otolaryngology" class="" data-icon-position="" data-hide-link-title="0">Otolaryngology</a> <span class = "article-count">(139)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pain-medicine" class="" data-icon-position="" data-hide-link-title="0">Pain Medicine</a> <span class = "article-count">(73)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/palliative-medicine" class="" data-icon-position="" data-hide-link-title="0">Palliative Medicine</a> <span class = "article-count">(30)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pathology" class="" data-icon-position="" data-hide-link-title="0">Pathology</a> <span class = "article-count">(195)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pediatrics" class="" data-icon-position="" data-hide-link-title="0">Pediatrics</a> <span class = "article-count">(410)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pharmacology-and-therapeutics" class="" data-icon-position="" data-hide-link-title="0">Pharmacology and Therapeutics</a> <span class = "article-count">(195)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/primary-care-research" class="" data-icon-position="" data-hide-link-title="0">Primary Care Research</a> <span class = "article-count">(158)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/psychiatry-and-clinical-psychology" class="" data-icon-position="" data-hide-link-title="0">Psychiatry and Clinical Psychology</a> <span class = "article-count">(1369)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/public-and-global-health" class="" data-icon-position="" data-hide-link-title="0">Public and Global Health</a> <span class = "article-count">(3057)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/radiology-and-imaging" class="" data-icon-position="" data-hide-link-title="0">Radiology and Imaging</a> <span class = "article-count">(509)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/rehabilitation-medicine-and-physical-therapy" class="" data-icon-position="" data-hide-link-title="0">Rehabilitation Medicine and Physical Therapy</a> <span class = "article-count">(244)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/respiratory-medicine" class="" data-icon-position="" data-hide-link-title="0">Respiratory Medicine</a> <span class = "article-count">(415)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/rheumatology" class="" data-icon-position="" data-hide-link-title="0">Rheumatology</a> <span class = "article-count">(158)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/sexual-and-reproductive-health" class="" data-icon-position="" data-hide-link-title="0">Sexual and Reproductive Health</a> <span class = "article-count">(118)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/sports-medicine" class="" data-icon-position="" data-hide-link-title="0">Sports Medicine</a> <span class = "article-count">(115)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/surgery" class="" data-icon-position="" data-hide-link-title="0">Surgery</a> <span class = "article-count">(153)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/toxicology" class="" data-icon-position="" data-hide-link-title="0">Toxicology</a> <span class = "article-count">(32)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/transplantation" class="" data-icon-position="" data-hide-link-title="0">Transplantation</a> <span class = "article-count">(67)</span></div></li>
<li class="outer collection depth-2  child last"><div class = "data-wrapper"><a href="/collection/urology" class="" data-icon-position="" data-hide-link-title="0">Urology</a> <span class = "article-count">(51)</span></div></li>
</ul>  </div>

  
  </div>
  </div>
</div>
</div>
</div>
  </div>

  
  </div>
</div>
			</div>
		</div>
	
	</div> <!-- /.panel-row-wrapper -->	
	
	</div>

    </div>
  </div>
</div>      </div>
</div>  </div>
</section>    
  
  </div>    <div class="region region-page-bottom" id="region-page-bottom">
  <div class="region-inner region-page-bottom-inner">
      </div>
</div><script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__Vh5BcRYb6VtLoN3uam6O4DIKltYUVMjVDWtakoysPq0__Wed8jsPTirEozek7dWSCS8970Cp7a9xKKgFk6FPuSVM__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.js"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BmqjBnkz3MgYCAoc25s1lDRMEjLhC3mEPVonUFIHi08__Unwv5-ZIuHBfFwytsjEx1niBVJ7n1T4lPws7VrkHXM4__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
function euCookieComplianceLoadScripts() {}
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
var eu_cookie_compliance_cookie_name = "";
//--><!]]>
</script>
  </body>
</html>
